Skip to main content

Table 3 Incidence of multiplicity colonic mucosal ulcer and dysplasia.

From: Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands

Group no.

Treatment

Incidence (%)

Multiplicity (no. of lesions / mouse, means ± SD)

  

Mucosal ulcer

Total dysplasia

Dysplasia with:

Mucosal ulcer

Total dysplasia

Dysplasia with:

    

Mild atypia

Severe atypia

  

Mild atypia

Severe atypia

1

AOM/DSS

40%

90%

80%

50%

0.5 ± 0.7

3.2 ± 1.5

1.4 ± 1.0

1.1 ± 1.3

2

AOM/DSS/0.04% Nimesulide

10%

90%

80%

50%

0.1 ± 0.3

2.2 ± 2.3

1.2 ± 0.9

0.6 ± 0.7

3

AOM/DSS/0.05% Troglitazone

20%

90%

50%

30%

0.3 ± 0.7

2.1 ± 2.2

0.7 ± 0.8

0.8 ± 1.6

4

AOM/DSS/0.05% Bezafibrate

30%

80%

60%

20%

0.4 ± 0.7

1.9 ± 1.8

0.9 ± 1.0

0.4 ± 0.8